Braveheart Bio
Braveheart Bio is a biotechnology startup in late clinical development, working on innovative treatments for hypertrophic cardiomyopathy and related disorders. Braveheart's small molecule therapy candidate, BHB-1893, is a selective cardiac myosin inhibitor designed to improve heart function in HCM patients. Overcontraction in HCM can result in thicker heart muscle and a decline in the heart's ability to fill and pump blood. HCM is among the most frequent uncommon diseases, affecting one in every 500 people in the United States.
Domain
braveheart.bio
Country
United StatesIndustry
BiotechnologyEmployees
1-10
Last Funding
$185.0M
Founded
2024
Tech Stack (16 technologies)
Frequently Asked Questions
What technologies does Braveheart Bio use?+
Braveheart Bio uses 16 technologies including Cabin, Google Font API, Google Tag Manager.
What industry is Braveheart Bio in?+
Braveheart Bio operates in the Biotechnology industry.
Where is Braveheart Bio based?+
Braveheart Bio is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026